Neuraxis (NRXS) director gets 21,598-share stock award

Rhea-AI Filing Summary

Neuraxis, Inc. director receives stock compensation. On 01/22/2026, the director was awarded 21,598 common shares at $4.63 per share as compensation for serving as an independent director. After this grant, the director beneficially owns 307,736 shares, including 286,138 shares held by Rosalind Master Fund L.P.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Aharon Gil

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	21,598	$4.63	$100K

Holdings After Transaction: Common Shares — 307,736 shares (Direct)

Footnotes (1)

1. Includes (1) 286,138 shares of common stock owned by Rosalind Master Fund L.P., and (2) 21,598 shares of common stock issued to the Reporting Person as compensation for services as an independent director of the Issuer. 21,598 shares of common stock were issued to the Reporting Person as compensation for services as independent director of the Issuer.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aharon Gil

(Last) (First) (Middle)

15 WELLESLEY STREET WEST

SUITE 326

(Street)

TORONTO A6 M4Y 0G7

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Neuraxis, INC [ NRXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	01/22/2026		A		21,598	A	$4.63(2)	307,736(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes (1) 286,138 shares of common stock owned by Rosalind Master Fund L.P., and (2) 21,598 shares of common stock issued to the Reporting Person as compensation for services as an independent director of the Issuer.

2. 21,598 shares of common stock were issued to the Reporting Person as compensation for services as independent director of the Issuer.

	/s/ Gilad Aharon	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Neuraxis (NRXS) disclose in this Form 4 filing?

Neuraxis reported that one of its directors received 21,598 common shares as stock compensation. The shares were granted on January 22, 2026, increasing the director’s total beneficial ownership to 307,736 shares of Neuraxis common stock, including shares held through Rosalind Master Fund L.P.

How many Neuraxis (NRXS) shares did the director receive and at what price?

The director received 21,598 Neuraxis common shares valued at $4.63 per share. This grant was issued as compensation for services as an independent director, rather than a market purchase, and is recorded as an acquisition of non-derivative securities on January 22, 2026.

What is the director’s total beneficial ownership in Neuraxis (NRXS) after this transaction?

After the grant, the director beneficially owns 307,736 Neuraxis common shares. This includes 286,138 shares owned by Rosalind Master Fund L.P. and the 21,598 shares issued directly to the director as compensation for serving as an independent director of Neuraxis.

Was this Neuraxis (NRXS) Form 4 transaction a stock purchase on the open market?

No, the 21,598 shares were issued as compensation, not bought on the open market. The filing explains they were granted to the director for services as an independent director, with a reported price of $4.63 per share for Form 4 reporting purposes.

How are Rosalind Master Fund L.P. shares related to the Neuraxis (NRXS) director’s holdings?

The filing states that 286,138 Neuraxis common shares are owned by Rosalind Master Fund L.P. and are included in the director’s beneficial ownership. Together with the new 21,598-share grant, these holdings total 307,736 shares attributed to the director.